Key Points
- CFO Matthew Ferguson purchased 60,000 shares on Dec. 17 at $0.53 each (~$31,800), boosting his stake to 447,110 shares — a 15.5% increase (he also bought smaller blocks on Dec. 1–2).
- Recent quarter: Elutia reported EPS of ($0.01) which beat estimates of ($0.16) but posted revenue of $3.32M versus $6.65M expected, and the consensus analyst rating is "Hold" with an average target of $7.00.
- Market snapshot: ELUT trades around $0.54 with a ~$23.2M market cap, a 12‑month range of $0.50–$4.84, and roughly 74% of shares held by hedge funds and institutional investors.
Elutia Inc. (NASDAQ:ELUT - Get Free Report) Director Brigid Makes purchased 25,000 shares of Elutia stock in a transaction dated Wednesday, December 17th. The stock was acquired at an average cost of $0.52 per share, with a total value of $13,000.00. Following the completion of the acquisition, the director directly owned 27,000 shares in the company, valued at approximately $14,040. This trade represents a 1,250.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Elutia Stock Up 5.0%
Shares of NASDAQ ELUT opened at $0.57 on Friday. The stock has a market capitalization of $24.34 million, a price-to-earnings ratio of -0.61 and a beta of 0.63. Elutia Inc. has a 52 week low of $0.50 and a 52 week high of $4.84. The firm has a 50-day moving average price of $0.77 and a 200 day moving average price of $1.44.
Elutia (NASDAQ:ELUT - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.15. The firm had revenue of $3.32 million for the quarter, compared to analysts' expectations of $6.65 million. Equities research analysts expect that Elutia Inc. will post -1.74 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have recently commented on ELUT. Weiss Ratings reiterated a "sell (e+)" rating on shares of Elutia in a report on Wednesday, October 8th. Lake Street Capital dropped their target price on Elutia from $8.00 to $6.00 and set a "buy" rating for the company in a research note on Wednesday, September 10th. Finally, Wall Street Zen raised Elutia to a "sell" rating in a research note on Saturday, November 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $7.00.
Check Out Our Latest Analysis on ELUT
Hedge Funds Weigh In On Elutia
Several hedge funds and other institutional investors have recently modified their holdings of the company. Knollwood Investment Advisory LLC increased its position in shares of Elutia by 10.7% in the first quarter. Knollwood Investment Advisory LLC now owns 1,034,617 shares of the company's stock worth $2,618,000 after acquiring an additional 100,000 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new stake in shares of Elutia in the 1st quarter worth about $28,000. Nantahala Capital Management LLC increased its holdings in Elutia by 11.2% in the first quarter. Nantahala Capital Management LLC now owns 3,184,947 shares of the company's stock valued at $8,058,000 after buying an additional 320,000 shares during the last quarter. Alyeska Investment Group L.P. raised its stake in Elutia by 310.8% during the first quarter. Alyeska Investment Group L.P. now owns 2,643,445 shares of the company's stock valued at $6,688,000 after buying an additional 2,000,000 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in Elutia during the 1st quarter worth approximately $48,000. 74.03% of the stock is owned by institutional investors and hedge funds.
About Elutia
(
Get Free Report)
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
